激光间质热疗在神经外科中的应用:单术者313例患者经验
该研究为2013至2023年单中心探索性队列分析,纳入313例接受LITT的脑肿瘤患者,平均随访10.4个月,66.8%存活,26.2%消融病灶复发,永久性神经功能缺损率14%(44例),平均复发时间12.2个月、总生存38.1个月,结论认为LITT是安全可行的消融治疗选择。
要点
- 313例接受LITT的患者中,永久性神经功能缺损率14%(44例),其中新发25例(8%),术前存在且未恢复19例(6.1%)。
- 平均随访10.4个月时66.8%存活、26.2%消融病灶复发;平均复发时间12.2个月、总生存38.1个月。
- 高级别病变是与肿瘤复发相关的单一因素;年龄、高级别病变、术前病灶体积及30天内再入院与总生存显著相关。
核心结论
- LITT是颅内病变安全可行的消融治疗选择,可能适用于其他方式不适合手术的特定患者。
研究设计与样本
- 单中心探索性队列分析,纳入2013年至2023年接受LITT的脑肿瘤患者313例,主要终点为消融范围、复发时间和总生存。
主要发现
- 平均随访10.4个月,66.8%患者存活,26.2%消融病灶复发;平均年龄60.4±13.3岁(女性58.5%)。
- 病变亚型包括转移瘤30%、胶质母细胞瘤41.6%、低级别胶质瘤9.1%、放射性坏死11.4%、脑膜瘤2.2%。
- 永久性神经功能缺损率14%(n=44),其中新发25例(8%)、术前存在且LITT后未恢复19例(6.1%)。
- 平均复发时间12.2个月、总生存38.1个月;复发时间和总生存随病变亚型显著不同(p<0.001,log-rank分析)。
- 多变量Cox回归显示年龄、高级别病变、术前病灶体积和30天内再入院与总生存显著相关;log-rank分析显示消融范围>100%预测转移瘤和胶质母细胞瘤的总生存更长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Real-time MRI-guided focused laser interstitial thermal therapy (LITT) is a minimally invasive surgical treatment choice for challenging intracranial lesions that are either resistant to conventional therapies or located in deep or critical areas of the brain. However, existing studies on LITT within surgical neuro-oncology are relatively small and have limited follow-up periods. The authors aimed to present a comprehensive analysis of their experiences with LITT in surgical neuro-oncology, with the intent to provide a clearer understanding of the safety and efficacy of this procedure. METHODS: This study was an exploratory cohort analysis encompassing all patients who underwent LITT for brain tumors at a single center between 2013 and 2023. The primary focus was extent of ablation (EOA), time to recurrence (TTR), and overall survival (OS). Secondary outcomes, including the rate of complications, were also evaluated. Comparative analyses were conducted based on lesion subtypes, and factors predicting outcomes were identified. RESULTS: Three hundred thirteen patients underwent LITT procedures. During a mean follow-up of 10.4 months, 66.8% of patients remained alive and 26.2% of the ablated lesions recurred. The mean age of the cohort was 60.4 ± 13.3 years (58.5% female). The lesion subtypes that were treated comprised metastases (30%), glioblastoma (GBM; 41.6%), low-grade glioma (9.1%), radiation necrosis (11.4%), and meningioma (2.2%). The permanent neurological deficit rate was 14% (n = 44), with 25 (8%) of them new-onset deficits and 19 deficits (6.1%) that were present preoperatively and did not resolve after LITT. The mean TTR and OS were 12.2 and 38.1 months, respectively. TTR and OS varied significantly by lesion subtype (p < 0.001, log-rank analysis). A high-grade lesion was identified as the single factor linked to tumor recurrence. Age, high-grade lesion, preoperative lesion volume, and readmission within 30 days were identified as factors significantly associated with OS in the multivariable Cox regression analysis. EOA > 100% predicted longer OS in metastases and GBM by log-rank analysis. CONCLUSIONS: LITT stands as a secure and feasible ablative treatment choice for intracranial lesions, potentially suitable for specific patient cases otherwise not amenable to surgical intervention. These findings further corroborate the safety of the procedure and its favorable outcomes, underscoring its potential significance in clinical practice.
引用
- Gurses ME, Lu VM, Gecici NN, et al. Laser interstitial thermal therapy in neurosurgery: a single-surgeon experience of 313 patients. J Neurosurg. 2024. PMID: 38820611. doi:10.3171/2024.3.JNS245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。